Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses novel approaches to chronic lymphocytic leukemia (CLL) treatment, including the use of single-agent targeted therapies such as venetoclax and ibrutinib over chemotherapy as well as T-cell based therapies for consolidation therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).